Published in Blood Weekly, January 12th, 2006
The update was given to a meeting of study investigators and European and Japanese hematologists.
Bioenvision reported a total of 37 patients have been enrolled to date in study BIOV-111, which is being conducted in 40 European centers (11 U.K.; 11 France; 9 Germany; 6 the Netherlands; 2 Italy; 1 Austria). Of the 20 evaluable patients, 5 (25%) have achieved, according to investigator assessment, a complete response (CR + CRp). "This is similar to the 20% complete...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.